LL-37 wound healing research is now one of the more compelling threads in human peptide science. The only known human cathelicidin peptide, LL-37 shows meaningful activity in tissue repair models. At TelosRX, it is available subject to medical approval by a licensed provider.
This article walks through what published research has actually found — framed as evidence, not clinical guidance. Compounded LL-37 is not FDA-approved. Every finding cited here comes from a peer-reviewed source; where data is preclinical only, that is stated clearly.
What Is LL-37 and Why Does Wound Research Focus on It?
LL-37 is a 37-amino-acid cationic peptide — the only cathelicidin produced naturally by the human body. It is generated mainly by neutrophils, macrophages, and epithelial cells in response to infection or tissue damage. “LL” refers to the two leucine residues at its N-terminus; “37” is its amino acid length.
Beyond antimicrobial activity (LL-37 disrupts bacterial membranes through electrostatic interaction), the peptide also modulates inflammation and signals epithelial cells to migrate and proliferate — both processes central to wound closure. This dual role — antimicrobial and regenerative — is what has driven wound healing research interest specifically.
For a foundational overview of LL-37 mechanisms, see our LL-37 research overview. This article focuses on the wound healing and tissue repair evidence specifically.
Finding 1 — LL-37 Is Depleted in Chronic Non-Healing Wounds
One of the pivotal early studies in LL-37 wound healing research measured cathelicidin expression across normal healing wounds and chronic non-healing wounds. Published in the Journal of Investigative Dermatology and available via ScienceDirect, the study found that chronic wounds — including venous leg ulcers — showed significantly reduced LL-37 expression compared to acute wounds progressing through normal healing stages.
The clinical implication: low LL-37 at the wound site may be a contributing mechanism to chronic wound failure, not merely a downstream consequence of it. The study found LL-37 deficiency correlated with impaired re-epithelialization — the process by which epithelial cells migrate across the wound bed to close the surface. This correlation suggested a potential therapeutic rationale for topical LL-37 in non-healing wound contexts.
Finding 2 — LL-37 Accelerates Re-Epithelialization in Tissue Repair Models
The same research group demonstrated that exogenous LL-37 application to wound models improved re-epithelialization and granulation tissue formation in both in vitro assays and in vivo mouse models. Keratinocytes — the cells responsible for covering a wound surface — migrated more rapidly toward the wound edge in the presence of LL-37 versus controls.
The proposed mechanism involves EGFR (epidermal growth factor receptor) activation. LL-37 appears to transactivate EGFR signaling, which drives keratinocyte proliferation and directional migration. The peptide also showed pro-angiogenic properties in some models — promoting new blood vessel formation, which supplies nutrients to healing tissue. These are preclinical findings; effects in human wound healing may differ in magnitude and context.
Finding 3 — Topical LL-37 Explored in Diabetic Foot Ulcer Research
Diabetic foot ulcers are among the most clinically challenging chronic wounds, characterized by impaired immune signaling, reduced local perfusion, and frequent bacterial colonization. A 2023 clinical study evaluated LL-37 cream applied to diabetic foot ulcers and reported improved wound closure rates in the LL-37 group compared to standard care, particularly in wounds with mild infection.
The study noted that LL-37’s combined antimicrobial and epithelialization-promoting properties may offer a mechanistic advantage in infection-complicated wounds where antibiotic resistance is a concern. This was a small clinical study — larger, controlled replication is needed before clinical practice implications can be drawn. This research is preliminary and should not be read as a claim about LL-37’s ability to address any disease.
Finding 4 — Broader Peptide Research Confirms LL-37’s Wound Role
A comprehensive 2024 review of peptides in wound healing — available via PubMed Central — surveyed multiple peptide classes and their activity in tissue repair. LL-37 and other beta-defensins were highlighted for their dual function: promoting fibroblast and keratinocyte activity while reducing pro-inflammatory cytokines that stall wound closure in chronic states. The authors concluded that antimicrobial peptides like LL-37 represent promising investigational agents, particularly in infection-complicated wound contexts where conventional antibiotics face resistance challenges.
LL-37 Wound Healing Mechanisms: Summary Table
| Mechanism | Effect on Wound Healing | Evidence Level |
|---|---|---|
| EGFR transactivation | Stimulates keratinocyte migration and proliferation | Preclinical (in vitro + animal) |
| Direct antimicrobial action | Reduces bacterial burden at wound site | Preclinical + early clinical |
| Fibroblast stimulation | Promotes granulation tissue and connective tissue synthesis | Preclinical |
| Immunomodulation | Modulates neutrophil activity, reduces excessive local inflammation | Preclinical |
| Pro-angiogenic signaling | May promote vascular supply to healing tissue | Preclinical (in vitro) |
The evidence is strongest at the preclinical level. Early clinical data in diabetic and chronic wounds is directionally consistent with the mechanistic model, but replication in larger trials is needed.
Accessing LL-37 Through a Compounded Protocol
LL-37 is not FDA-approved and is available as a compounded peptide through licensed telehealth providers who include it in their protocol catalog. TelosRX operates as an asynchronous online-first telehealth service — you complete intake and health history online, and a licensed provider reviews your case and responds without a scheduled call.
If tissue repair is a primary interest, you may also want to explore the research on BPC-157 — studied in tendon, ligament, and gut repair models — as a complementary approach within a provider-supervised protocol. All compounded peptide access is subject to medical approval by a licensed provider.
Explore the full TelosRX peptide research library, or start your private evaluation to discuss LL-37 as part of your wellness plan.
Frequently Asked Questions
What does LL-37 do for wounds?
Preclinical research suggests LL-37 promotes keratinocyte migration, activates fibroblasts, provides antimicrobial protection at the wound site, and modulates local inflammation — all processes involved in tissue closure. Its dual antimicrobial and regenerative activity is the primary research focus in wound applications.
Is LL-37 FDA-approved for wound healing?
No. Compounded LL-37 is not FDA-approved. It is an investigational peptide available through licensed compounding providers. All use is subject to medical approval by a licensed provider, and individual outcomes vary. This article summarizes published research, not clinical recommendations.
What is cathelicidin LL-37?
Cathelicidin LL-37 is the only human-produced cathelicidin — an antimicrobial host defense peptide stored in neutrophil granules and expressed by epithelial cells. Released in response to infection or tissue damage, it acts against bacteria and also signals tissue repair processes through EGFR and other pathways.
Are LL-37 levels lower in diabetic wounds?
Research suggests chronic wounds — including diabetic ulcers — show reduced LL-37 expression compared to acutely healing wounds. This depletion may contribute to impaired closure, which is the mechanistic rationale for topical LL-37 research in diabetic foot ulcers. Evidence is preliminary.
How does LL-37 compare to BPC-157 for tissue repair?
LL-37 and BPC-157 address tissue repair through different mechanisms. LL-37 primarily works at wound surfaces — antimicrobial, keratinocyte-stimulating, and immunomodulatory. BPC-157 is studied mainly in tendon, muscle, and gut repair via growth factor pathways. They are not interchangeable; a licensed provider can assess which research context fits your situation.
Can LL-37 be taken orally?
Oral bioavailability of LL-37 is low — it degrades significantly in the gastrointestinal tract. Research and clinical use focus on topical application for wound sites and subcutaneous or intranasal delivery. Administration route is determined by your licensed provider, subject to medical approval.
Where is LL-37 naturally found in the body?
LL-37 is produced by neutrophils, macrophages, monocytes, mast cells, and epithelial cells lining the skin, lungs, and gut. It functions as a first-responder host defense peptide — released rapidly when tissue encounters infection or physical damage.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.